Meiji Yasuda Asset Management Co Ltd. boosted its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 7.6% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 35,745 shares of the medical research company’s stock after buying an additional 2,522 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Thermo Fisher Scientific were worth $5,490,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Wellington Management Group LLP boosted its stake in Thermo Fisher Scientific by 5.6% in the first quarter. Wellington Management Group LLP now owns 7,512,152 shares of the medical research company’s stock valued at $1,153,867,000 after buying an additional 398,622 shares during the period. Pictet Asset Management Ltd. boosted its stake in Thermo Fisher Scientific by 1.2% in the first quarter. Pictet Asset Management Ltd. now owns 2,407,464 shares of the medical research company’s stock valued at $369,786,000 after buying an additional 29,513 shares during the period. Pioneer Investment Management Inc. boosted its stake in Thermo Fisher Scientific by 1.6% in the first quarter. Pioneer Investment Management Inc. now owns 2,219,085 shares of the medical research company’s stock valued at $340,851,000 after buying an additional 34,012 shares during the period. Findlay Park Partners LLP boosted its stake in Thermo Fisher Scientific by 20.8% in the first quarter. Findlay Park Partners LLP now owns 2,032,151 shares of the medical research company’s stock valued at $312,138,000 after buying an additional 350,000 shares during the period. Finally, C WorldWide Group Holding A S boosted its stake in Thermo Fisher Scientific by 997.1% in the first quarter. C WorldWide Group Holding A S now owns 1,950,049 shares of the medical research company’s stock valued at $299,527,000 after buying an additional 1,772,300 shares during the period. Institutional investors own 87.60% of the company’s stock.
Shares of Thermo Fisher Scientific Inc (NYSE:TMO) opened at 172.57 on Friday. The firm has a 50-day moving average of $176.71 and a 200 day moving average of $166.56. The company has a market cap of $67.32 billion, a price-to-earnings ratio of 30.06 and a beta of 1.06. Thermo Fisher Scientific Inc has a 12 month low of $139.07 and a 12 month high of $182.87.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The firm had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. During the same period last year, the firm posted $2.03 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 10.2% compared to the same quarter last year. On average, analysts expect that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.35%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.45%.
TRADEMARK VIOLATION WARNING: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.com-unik.info/2017/08/19/thermo-fisher-scientific-inc-tmo-position-boosted-by-meiji-yasuda-asset-management-co-ltd-updated.html.
TMO has been the subject of several recent analyst reports. Bank of America Corporation reiterated a “buy” rating and set a $210.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Barclays PLC set a $175.00 price target on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Wednesday, April 26th. Cantor Fitzgerald initiated coverage on shares of Thermo Fisher Scientific in a report on Thursday, May 18th. They set an “overweight” rating and a $194.00 price objective for the company. Finally, Cowen and Company reiterated an “outperform” rating and set a $185.00 price objective (up from $175.00) on shares of Thermo Fisher Scientific in a report on Saturday, April 29th. One investment analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Thermo Fisher Scientific presently has a consensus rating of “Buy” and a consensus price target of $188.56.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 20,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the completion of the transaction, the chief executive officer now directly owns 269,279 shares of the company’s stock, valued at $46,528,718.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction on Monday, June 5th. The stock was sold at an average price of $176.26, for a total transaction of $440,650.00. Following the transaction, the chief financial officer now directly owns 37,790 shares of the company’s stock, valued at $6,660,865.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 39,506 shares of company stock valued at $6,834,758. 0.49% of the stock is currently owned by insiders.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
What are top analysts saying about Thermo Fisher Scientific Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Thermo Fisher Scientific Inc and related companies.